216 related articles for article (PubMed ID: 30739906)
1. Myosin Heavy Chain 9: Oncogene or Tumor Suppressor Gene?
Wang Y; Liu S; Zhang Y; Yang J
Med Sci Monit; 2019 Jan; 25():888-892. PubMed ID: 30739906
[TBL] [Abstract][Full Text] [Related]
2. Altered cytoskeleton organization in platelets from patients with MYH9-related disease.
Canobbio I; Noris P; Pecci A; Balduini A; Balduini CL; Torti M
J Thromb Haemost; 2005 May; 3(5):1026-35. PubMed ID: 15869600
[TBL] [Abstract][Full Text] [Related]
3. Mutations responsible for MYH9-related thrombocytopenia impair SDF-1-driven migration of megakaryoblastic cells.
Pecci A; Bozzi V; Panza E; Barozzi S; Gruppi C; Seri M; Balduini CL
Thromb Haemost; 2011 Oct; 106(4):693-704. PubMed ID: 21833445
[TBL] [Abstract][Full Text] [Related]
4. Haematological characteristics of MYH9 disorders due to MYH9 R702 mutations.
Kunishima S; Yoshinari M; Nishio H; Ida K; Miura T; Matsushita T; Hamaguchi M; Saito H
Eur J Haematol; 2007 Mar; 78(3):220-6. PubMed ID: 17241369
[TBL] [Abstract][Full Text] [Related]
5. Analysis of clinical manifestations, mutant gene and encoded protein in two Chinese MYH9-related disease families.
Yi Y; Sen Zhang G; Xu M; San Ling Z; Ru Shao X; Zeng Li J; Ma J
Clin Chim Acta; 2006 Nov; 373(1-2):49-54. PubMed ID: 16806139
[TBL] [Abstract][Full Text] [Related]
6. Advances in the understanding of MYH9 disorders.
Kunishima S; Saito H
Curr Opin Hematol; 2010 Sep; 17(5):405-10. PubMed ID: 20601875
[TBL] [Abstract][Full Text] [Related]
7. Pathogenetic mechanisms of hematological abnormalities of patients with MYH9 mutations.
Pecci A; Canobbio I; Balduini A; Stefanini L; Cisterna B; Marseglia C; Noris P; Savoia A; Balduini CL; Torti M
Hum Mol Genet; 2005 Nov; 14(21):3169-78. PubMed ID: 16162639
[TBL] [Abstract][Full Text] [Related]
8. Nonmuscle Myosin Heavy Chain IIA Mutation Predicts Severity and Progression of Sensorineural Hearing Loss in Patients With MYH9-Related Disease.
Verver EJ; Topsakal V; Kunst HP; Huygen PL; Heller PG; Pujol-Moix N; Savoia A; Benazzo M; Fierro T; Grolman W; Gresele P; Pecci A
Ear Hear; 2016; 37(1):112-20. PubMed ID: 26226608
[TBL] [Abstract][Full Text] [Related]
9. MYH9-Related Thrombocytopenia: Four Novel Variants Affecting the Tail Domain of the Non-Muscle Myosin Heavy Chain IIA Associated with a Mild Clinical Evolution of the Disorder.
Zaninetti C; De Rocco D; Giangregorio T; Bozzi V; Demeter J; Leoni P; Noris P; Ryhänen S; Barozzi S; Pecci A; Savoia A
Hamostaseologie; 2019 Feb; 39(1):87-94. PubMed ID: 29996171
[TBL] [Abstract][Full Text] [Related]
10. MYH9: Structure, functions and role of non-muscle myosin IIA in human disease.
Pecci A; Ma X; Savoia A; Adelstein RS
Gene; 2018 Jul; 664():152-167. PubMed ID: 29679756
[TBL] [Abstract][Full Text] [Related]
11. Non-muscle myosin heavy chain IIA and IIB interact and co-localize in living cells: relevance for MYH9-related disease.
Marini M; Bruschi M; Pecci A; Romagnoli R; Musante L; Candiano G; Ghiggeri GM; Balduini C; Seri M; Ravazzolo R
Int J Mol Med; 2006 May; 17(5):729-36. PubMed ID: 16596254
[TBL] [Abstract][Full Text] [Related]
12. The abnormal proplatelet formation in MYH9-related macrothrombocytopenia results from an increased actomyosin contractility and is rescued by myosin IIA inhibition.
Chen Y; Boukour S; Milloud R; Favier R; Saposnik B; Schlegel N; Nurden A; Raslova H; Vainchenker W; Balland M; Nurden P; Debili N
J Thromb Haemost; 2013 Dec; 11(12):2163-75. PubMed ID: 24165359
[TBL] [Abstract][Full Text] [Related]
13. Differential expression of wild-type and mutant NMMHC-IIA polypeptides in blood cells suggests cell-specific regulation mechanisms in MYH9 disorders.
Kunishima S; Hamaguchi M; Saito H
Blood; 2008 Mar; 111(6):3015-23. PubMed ID: 18192507
[TBL] [Abstract][Full Text] [Related]
14. Renal injury associated with
Yoshikawa K; Kunishima S; Kurihara H; Takahashi K; Fukuta A; Murai K; Echizenya T; Nakaya I; Soma J
Clin Nephrol; 2023 Mar; 99(3):153-160. PubMed ID: 36602281
[TBL] [Abstract][Full Text] [Related]
15. Megakaryocytes of patients with MYH9-related thrombocytopenia present an altered proplatelet formation.
Pecci A; Malara A; Badalucco S; Bozzi V; Torti M; Balduini CL; Balduini A
Thromb Haemost; 2009 Jul; 102(1):90-6. PubMed ID: 19572073
[TBL] [Abstract][Full Text] [Related]
16. Clinical manifestation and molecular genetic characterization of MYH9 disorders.
Provaznikova D; Geierova V; Kumstyrova T; Kotlin R; Mikulenkova D; Zurkova K; Matoska V; Hrachovinova I; Rittich S
Platelets; 2009 Aug; 20(5):289-96. PubMed ID: 19557653
[TBL] [Abstract][Full Text] [Related]
17. MYH9-related platelet disorders.
Althaus K; Greinacher A
Semin Thromb Hemost; 2009 Mar; 35(2):189-203. PubMed ID: 19408192
[TBL] [Abstract][Full Text] [Related]
18. Immunocytochemistry for the heavy chain of the non-muscle myosin IIA as a diagnostic tool for MYH9-related disorders.
Pecci A; Noris P; Invernizzi R; Savoia A; Seri M; Ghiggeri GM; Sartore S; Gangarossa S; Bizzaro N; Balduini CL
Br J Haematol; 2002 Apr; 117(1):164-7. PubMed ID: 11918549
[TBL] [Abstract][Full Text] [Related]
19. [Genetic analysis of a pedigree affected with inherited thrombocytopenia caused by a novel mutation of MYH9 gene].
Liao W; Luo X; Zhang X; Chen P; Wu H; Shu W; Yuan Z
Zhonghua Yi Xue Yi Chuan Xue Za Zhi; 2017 Jun; 34(3):352-356. PubMed ID: 28604953
[TBL] [Abstract][Full Text] [Related]
20. Identification of the first in cis mutations in MYH9 disorder.
Miyajima Y; Kunishima S
Eur J Haematol; 2009 Apr; 82(4):288-91. PubMed ID: 19191864
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
